Every 424B that Myseum.AI, Inc. (MYSE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MYSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYSE filings page.
Myseum.AI, Inc. (MYSE) updates its at-the-market offering to cover up to $2,754,500 of common stock still available for sale under an existing Form S-3 shelf registration. The company has already sold 750,000 shares for gross proceeds of approximately $3.3 million under this program.
As of September 21, 2026, the Sales Agreement has been amended so that StoneX Financial Inc., an SEC-registered broker-dealer and FINRA/SIPC member, replaces The Benchmark Company, LLC as sales agent. The offering remains subject to the Form S-3 public float limit under General Instruction I.B.6. MYSE common stock trades on the Nasdaq Capital Market, with a last reported sale price of $1.98 per share on September 18, 2026.
Myseum.AI, Inc. files an Amendment No. 1 to its prospectus supplement to increase the amount of common stock it may sell under its Sales Agreement with The Benchmark Company, LLC.
The Amendment adds up to $2,754,500 of common stock available for issuance and sale under the Sales Agreement, in addition to 750,000 shares previously sold for gross proceeds of approximately $3.3 million. The company reports 5,081,274 shares outstanding, with a public float value of approximately $18,237,547 based on $3.81 per share (the highest closing price within the prior 60 days). The last reported sale price on April 22, 2026 was $3.37 per share.
Myseum, Inc. is offering up to $3,500,000 of common stock through an at-the-market program with The Benchmark Company under an existing shelf registration. Benchmark will sell shares on Nasdaq as agent or principal on a best-efforts basis.
Benchmark earns a 4% commission on gross proceeds, which drops to 3% once cumulative sales under the agreement exceed $1,000,000. Myseum plans to use any net proceeds mainly for working capital, general corporate purposes and potential future acquisitions. The company notes that sales under this program can cause dilution and that its public float was about $10.7 million as of December 10, 2025.